Pfizer's growth strategy for the 2024–2030 period is organized around four explicit priorities: oncology leadership through the Seagen integration and ADC pipeline, mRNA platform expansion beyond COVID vaccines, pipeline execution in rare disease and immunology, and cost efficiency to restore margins during the revenue rebuilding phase. The oncology growth strategy is the most capital-intensive and strategically consequential. The Seagen acquisition brought immediate revenue (the four approved Seagen products generated approximately $3.4 billion in combined 2022 revenues before acquisition) and a deep ADC pipeline with multiple candidates in Phase 2 and Phase 3 trials. Pfizer's investment thesis is that ADCs will capture an increasing share of oncology treatment, across both hematologic malignancies and solid tumors, and that owning a leading ADC platform positions the company for disproportionate participation in this growth. Pfizer has guided for Seagen-origin products to contribute $10 billion in incremental revenues by 2030 — an ambitious but achievable target if multiple pipeline candidates advance successfully. The mRNA platform expansion builds on the proven manufacturing and formulation capability established through Comirnaty. The most advanced non-COVID mRNA program is the RSV (respiratory syncytial virus) vaccine — a market where Pfizer is competing against GSK (Arexvy, approved 2023) and Moderna. RSV causes approximately 160,000 hospitalizations and 10,000 deaths annually in the US among adults 60+, making it a large and commercially validated market. Pfizer's mRNA RSV vaccine candidate, if approved, would complete the respiratory vaccine franchise alongside Comirnaty and the influenza mRNA vaccine in development. The rare disease pipeline, anchored by the hemophilia gene therapy program (Beqvez, approved 2024) and additional programs in rare genetic disorders, represents a strategic expansion into high-pricing, small-volume specialty products. Gene therapies for rare diseases can command pricing of $1–3 million per patient — among the highest in medicine — reflecting the potentially curative nature of single-treatment interventions. Pfizer's manufacturing expertise in complex biological products, acquired through decades of sterile injectable and biologics production, provides a credible capability foundation for gene therapy scale-up.